Navigation Links
Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6

SAN DIEGO, April 29, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report first quarter 2011 financial results on Friday, May 6, 2011 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PDT (11:00 a.m. EDT), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the first quarter of 2011 and provide a product pipeline update.


To participate by telephone, please dial 877.407.8037 for domestic callers or 201.689.8037 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's Web site at Shortly after the call an audio replay will be available on Halozyme's Web site for seven days. A telephone replay will be available by dialing 877.660.6853 from the U.S., or 201.612.7415 for international callers and using account # 367 and ID # 371588.  

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche and Baxter to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, and immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit

Halozyme Contact  
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
2. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
3. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
4. Halozyme Therapeutics Realigns Management
5. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
6. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
7. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
8. Halozyme Therapeutics Announces Public Offering of Common Stock
9. Halozyme Provides HYLENEX® Product Reintroduction Update
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that will ... their purchase of lice treatment product. In addition, customers will receive a complimentary head ... “Finding lice is a sure way to ruin the holidays, so we encourage all ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in ... for mental health and wellness consultation, has collaborated with a leading web-based marketplace ... knowledge gap experienced by parents and bring advice from parenting experts within their ...
(Date:11/27/2015)... California (PRWEB) , ... November 27, 2015 , ... Avid ... Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most ... the Canterbury House at the University of Michigan in Ann Arbor. The According to ...
(Date:11/26/2015)... and Cambridge, ON (PRWEB) , ... November 26, ... ... the availability of a real-time eReferral system for diagnostic imaging in the Waterloo ... X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical record ...
Breaking Medicine News(10 mins):